ApoB (Apolipoprotein B)
The real marker of cardiovascular risk — better than LDL-cholesterol alone
Definition
Apolipoprotein B-100 (ApoB) is the main structural protein of all atherogenic lipoproteins: LDL, VLDL, IDL, and Lp(a). Each particle contains exactly one ApoB molecule, so its measurement directly quantifies the total number of atherogenic particles circulating in blood. It is the most accurate predictor of cardiovascular events according to the European Atherosclerosis Society consensus (2017) and outperforms traditional LDL-cholesterol when the two disagree.
Detailed explanation
The discrepancy between LDL-C and ApoB is clinically relevant: two people can have the same LDL-cholesterol but very different ApoB if their particles are large and few (less atherogenic) versus small, dense and many (highly atherogenic). This is the typical case of the metabolic phenotype — insulin resistance, high triglycerides, low HDL, elevated ApoB despite relatively normal LDL-C.
The goals in longevity medicine are more aggressive than conventional guidelines: ApoB <60 mg/dL in advanced primary prevention; <50 mg/dL in secondary prevention or in patients with elevated Lp(a). Peter Attia recommends targets close to 30-40 mg/dL in his book Outlive.
Interventions that consistently lower ApoB: Mediterranean diet, visceral fat loss, omega-3 fatty acids (≥2 g/day EPA+DHA), statins, ezetimibe, and PCSK9 inhibitors. It is essential to measure it fasting for standardised results.
Scientific sources
- PubMed — Apolipoprotein B particles and cardiovascular disease: a narrative review
- PubMed — Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction
- PubMed — European Atherosclerosis Society consensus on apoB
- PubMed — Discordance between apoB, non-HDL-C, and LDL-C: clinical implications
Related terms
Interested in related treatments?
Generate My Protocol